<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666016</url>
  </required_header>
  <id_info>
    <org_study_id>WN29850</org_study_id>
    <secondary_id>TRO19622 CL E Q 1159-1</secondary_id>
    <nct_id>NCT00666016</nct_id>
  </id_info>
  <brief_title>Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>Double-Blind vs Placebo, Randomized, Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 500 mg QD for One Month in Patients With Non-Alcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, the tolerability and the short term effect&#xD;
      on liver enzymes of TRO19622 500 mg for one month in patients with Non-Alcoholic&#xD;
      Steatohepatitis (NASH).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in ALT as assessed by an ANCOVA with the following covariates: treatment, gender, subject and time and a non parametric test (Conover-Salsburg).</measure>
    <time_frame>Mean change in ALT at V1 (Day15) and V2 (Day 30)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained reduction in ALT to either 50% of baseline or value &lt; or equal to ULN. Sustained reduction serum AST and GGT.Clinical and laboratory safety.</measure>
    <time_frame>V1 (Day 15), V2 (Day 30) and V3 (Day 60)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Non-Alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRO19622 500 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRO19622</intervention_name>
    <description>TRO19622 500 mg once a day before noon meal during 6 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects older than 18 years.&#xD;
&#xD;
          -  Persistent ALT elevation (&gt; 2 times the ULN of the local laboratory of the&#xD;
             investigating site) over 6 months prior to entry into study.&#xD;
&#xD;
               -  No more than one ALT value within the normal range in the past year.&#xD;
&#xD;
               -  Patients must have had an ALT measurement at least once every 6 months within the&#xD;
                  year before inclusion.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of steatohepatitis on biopsy within 2 years prior&#xD;
             to entry into protocol.&#xD;
&#xD;
          -  Compensated liver disease with the following hematologic, biochemical, and serological&#xD;
             criteria on entry into protocol:&#xD;
&#xD;
               -  Hemoglobin &gt; 11 gm/dL for females and &gt; 12 gm/dL for males&#xD;
&#xD;
               -  White blood cell (WBC) &gt; 2.5 K/UL&#xD;
&#xD;
               -  Neutrophil count &gt; 1.5 K/UL&#xD;
&#xD;
               -  Platelets &gt; 100 K/UL&#xD;
&#xD;
               -  Total bilirubin &lt; 35 µmol/L)&#xD;
&#xD;
               -  Albumin &gt; 36 g/L&#xD;
&#xD;
               -  TP &gt; 80% .&#xD;
&#xD;
               -  Serum creatinine within normal limits&#xD;
&#xD;
          -  No other cause of chronic liver disease (autoimmune,primary biliary cirrhosis, HBV,&#xD;
             Wilson, alpha-1-antitrypsin deficit, hemochromatosis etc\dots )&#xD;
&#xD;
          -  If applicable, have a stable diabetes, defined as HbA1c &lt; 9% and fasting glycemia &lt; 10&#xD;
             mmol/L,no changes in medication in the previous 6 months, and no new symptoms&#xD;
             associated with diabetes in the previous 3 months.&#xD;
&#xD;
          -  If applicable have a stable metabolic condition (diagnosis made at least 6 months&#xD;
             before inclusion), without major weight or laboratory tests changes.&#xD;
&#xD;
          -  Negative pregnancy test or post menopausal.&#xD;
&#xD;
          -  Have an electrocardiogram (ECG) without any clinically significant abnormality.&#xD;
&#xD;
          -  Subjects must be willing to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of another form of liver disease.&#xD;
&#xD;
          -  History of excess alcohol ingestion: daily alcohol consumption &gt;30 g/day (3 drinks per&#xD;
             day) for males and &gt;20 g/day (2 drinks/day) for females.&#xD;
&#xD;
          -  Unstable metabolic condition: Weight change &gt; +/- 10% in the previous year, diabetes&#xD;
             with poor glycemic control (HbA1c &gt;9%),introduction of an antidiabetic or of an&#xD;
             anti-obesity drug in the past 6 months prior to screening.&#xD;
&#xD;
          -  History of gastrointestinal bypass surgery or ingestion of drugs known to produce&#xD;
             hepatic steatosis including corticosteroids,high-dose estrogens, methotrexate,&#xD;
             tetracycline or amiodarone in the previous 6 months.&#xD;
&#xD;
          -  Significant systemic or major illnesses other than liver disease,including congestive&#xD;
             heart failure, coronary artery disease, cerebrovascular disease, pulmonary disease,&#xD;
             renal failure, organ transplantation, serious psychiatric disease,malignancy that, in&#xD;
             the opinion of the investigator would preclude treatment with TRO19622 and/or adequate&#xD;
             follow up.&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Active substance abuse, such as inhaled or injection drugs within the previous year.&#xD;
&#xD;
          -  Pregnancy or inability to practice adequate contraception in women of child-bearing&#xD;
             potential.&#xD;
&#xD;
          -  Active malignancy except cutaneous basocellular carcinoma.&#xD;
&#xD;
          -  Any other condition which, in the opinion of the investigator would impede competence&#xD;
             or compliance or possibly hinder completion of the study.&#xD;
&#xD;
          -  Body mass index (BMI) &gt;40 kg/m2 (obesity Grade III).&#xD;
&#xD;
          -  Type 1 diabetes or Insulin-treated type 2 diabetes.&#xD;
&#xD;
          -  Hemostasis disorders or current treatment with anticoagulants.&#xD;
&#xD;
          -  History of, or current cardiac dysrhythmias and / or a history of cardiovascular&#xD;
             disease, including myocardial infarction, except patients with only well controlled&#xD;
             hypertension.&#xD;
&#xD;
          -  Participation in any other investigational drug or therapy study within the previous 3&#xD;
             months.&#xD;
&#xD;
          -  Be possibly dependent on the Investigator or the Sponsor (eg, including, but not&#xD;
             limited to, affiliated employee).&#xD;
&#xD;
          -  Medications that could interfere with TRO19622 absorption&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vlad Ratziu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GH PITIE-SALPETRIERE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Archet 2 - Pôle de Référence Hépatite C (Niveau -2) - 151, route Saint Antoine de Ginestière</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpétrière - Sce Hépato-Gastroentérologie - 47-83 Bd de l'Hôpital</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non alcoholic steatohepatitis nash hepatoprotective hepatoprotection ALT AST new drug candidate interventional study TRO19622 Trophos cholest-4-en-3-one oxime</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

